Live Breaking News & Updates on Glp 1 receptor agonist
Stay updated with breaking news from Glp 1 receptor agonist. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
1. Semaglutide showed significant improvements in KCCQ-CSS score and reduction in body weight compared to placebo. 2. There were fewer serious adverse events in the semaglutide group. Evidence Rating Level: 1 (Excellent) Study Rundown: Obesity and diabetes lead to poor prognosis in patients with heart failure. GLP-1 receptor agonists, such as semaglutide, have been shown